Compare MAXN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAXN | APLT |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 38.1M |
| IPO Year | N/A | 2019 |
| Metric | MAXN | APLT |
|---|---|---|
| Price | $3.40 | $0.11 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.25 |
| AVG Volume (30 Days) | 72.1K | ★ 27.2M |
| Earning Date | 03-06-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,414,000.00 | $1,000,000.00 |
| Revenue This Year | $100.37 | $124.18 |
| Revenue Next Year | $24.61 | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.49 | $0.11 |
| 52 Week High | $9.05 | $1.50 |
| Indicator | MAXN | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 25.17 |
| Support Level | $2.92 | $0.21 |
| Resistance Level | $3.73 | $0.26 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 57.61 | 7.83 |
Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, Italy, and Rest of world.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.